Allen Institute for Cell Science Debuts First Comprehensive View of Human Cell Division
Allen Institute for Cell Science Debuts First Comprehensive View of Human Cell Division

The Allen Institute today released the Integrated Mitotic Stem Cell, a data-driven model and visualization tool that captures - for the first time - a holistic view of human cell division. By enabling a deeper...

Akrevia Therapeutics Appoints Rene´ Russo, PharmD, as Chief Executive Officer
Akrevia Therapeutics Appoints Rene´ Russo, PharmD, as Chief Executive Officer

Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, today announced that Rene´ Russo, PharmD, has been appointed as Chief...

OncoSec Medical Incorporated Prices $11,000,000 Public Offering
OncoSec Medical Incorporated Prices $11,000,000 Public Offering

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced the pricing of an underwritten public offering led by...

CollPlant Launches New HQ and R&D Center in Israel
CollPlant Launches New HQ and R&D Center in Israel

CollPlant (NASDAQ: CLGN), a regenerative medicine company, has launched a new HQ and R&D center in Israel.

Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress
Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress

Vitaeris Inc. (Vitaeris) today announced that eight abstracts involving or related to clazakizumab, Vitaeris' proprietary anti-interleukin-6 humanized monoclonal antibody, have been accepted for presentation at the...

Prometic presents new PBI-4050 and Ryplazim™ (plasminogen) data on lung fibrosis at the 2019 ATS Conference
Prometic presents new PBI-4050 and Ryplazim™ (plasminogen) data on lung fibrosis at the 2019 ATS Conference

LAVAL, QC and CAMBRIDGE, United Kingdom, May 22, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of three scientific posters on the Company's lead...

OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer
OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a late-stage cancer biotechnology company developing gene-based intratumoral immunotherapies, today announces interim data from KEYNOTE-890, an ongoing Phase 2 study of...

Digital PCR (dPCR) and Real-time PCR (qPCR) Market Worth $6.3 Billion by 2024 - Exclusive Report by MarketsandMarkets™
Digital PCR (dPCR) and Real-time PCR (qPCR) Market Worth $6.3 Billion by 2024 - Exclusive Report by MarketsandMarkets™

According to the new market research report "Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents, Software, Services), Application (Clinical, Oncology, Forensics), End-user (Hospitals,...

HighRes Biosolutions and TetraScience integrate technology to provide R&D labs with next-generation lab automation
HighRes Biosolutions and TetraScience integrate technology to provide R&D labs with next-generation lab automation

HighRes Biosolutions and TetraScience announce a new partnership to integrate their flagship products to automate data collection and manipulation processes in life sciences lab automation. The integration streamlines data...

Crown Laboratories Acquires Xycrobe™ Therapeutics, Inc., an Innovator in Skin Microbiome Technology
Crown Laboratories Acquires Xycrobe™ Therapeutics, Inc., an Innovator in Skin Microbiome Technology

Crown Laboratories, Inc. ("Crown"), a leading, fully integrated skin care company, today announced it has acquired Xycrobe Therapeutics, Inc. ("Xycrobe").

Ampio Clinical, Regulatory and Corporate Update
Ampio Clinical, Regulatory and Corporate Update

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates on subjects of interest to shareholders.

Epic Sciences Appoints New Chief Technology Officer
Epic Sciences Appoints New Chief Technology Officer

Epic Sciences, Inc. today announced that it has named Chockalingam "Palani" Palaniappan as its new chief technology officer (CTO) to help the company advance its Functional Cell Profiling technology to drive global...

Locana Raises $55 Million Series A Financing to Advance Portfolio of RNA-targeting Gene Therapies
Locana Raises $55 Million Series A Financing to Advance Portfolio of RNA-targeting Gene Therapies

Locana, Inc., a leading RNA-targeting gene therapy company, announced today the close of a $55 million Series A financing led by ARCH Venture Partners with participation from Temasek and Lightstone Ventures, all existing...

Wild Earth Closes Series A with $11 Million from VegInvest, Bits x Bites, VECTR, P.O.V., and M Ventures
Wild Earth Closes Series A with $11 Million from VegInvest, Bits x Bites, VECTR, P.O.V., and M Ventures

Wild Earth, Inc., a startup reinventing pet food with biotech, today announced it has closed its Series A with an investment of $11 million led by VegInvest, a venture capital firm supporting early-stage companies striving...

BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea
BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced today that the last patient in the Company's Phase 2b clinical...

EpiBone, Inc. Receives FDA Clearance to Commence its First-In-Human, Phase 1/2 Trial of its Bone Product, EB-CMF
EpiBone, Inc. Receives FDA Clearance to Commence its First-In-Human, Phase 1/2 Trial of its Bone Product, EB-CMF

EpiBone, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted its Investigational New Drug (IND) clearance to proceed with a Phase 1/2 clinical trial of its lead bone product...

Scientist.com Partners with Women In Bio - Southern California to Celebrate a Century of Women in Science
Scientist.com Partners with Women In Bio - Southern California to Celebrate a Century of Women in Science

Scientist.com, the marketplace for medical research, is proud to announce that it has partnered with Women In Bio of Southern California (WIB-SoCal) to celebrate the 100th anniversary of the passing of the 19th Amendment....

89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100, an Investigational Medicine for NASH
89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100, an Investigational Medicine for NASH

89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today announced positive top-line results from a Phase 1 single ascending dose...

Invitae to Present at the 2019 William Blair Growth Stock Conference
Invitae to Present at the 2019 William Blair Growth Stock Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae will present at the 2019 William Blair Growth Stock Conference on...

Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting
Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its mental health portfolio at the American Society of Clinical Psychopharmacology (ASCP) 2019 Annual Meeting in Scottsdale, Ariz., May 28-31,...

Dr. David Greene and R3 Stem Cell Heroes Program Now Offering Teachers Complimentary Regenerative Therapies
Dr. David Greene and R3 Stem Cell Heroes Program Now Offering Teachers Complimentary Regenerative Therapies

The R3 Stem Cell Heroes Program is now including teachers in the nomination process for who can receive complimentary regenerative therapies. R3 Founder Dr. David Greene started the program to help give back to military...

Leo Kawai, PhD, Distinguished Translational Drug Research and Development Expert, Joins NDA Partners
Leo Kawai, PhD, Distinguished Translational Drug Research and Development Expert, Joins NDA Partners

NDA Partners Chairman Carl Peck, MD, announced today that Leo Kawai, PhD, an international scientist and distinguished expert on translational drug research and development, has joined the firm as an Expert Consultant. Dr....

BioInvent Interim Report January 1 - March 31, 2019
BioInvent Interim Report January 1 - March 31, 2019

Net sales SEK 17.4 (11.3) millionEarnings after tax SEK -27.8 (-24.9) million Earnings after tax per share before and after dilution: SEK -0.08 (-0.08) SEKLiquid funds as of March 31, 2019 SEK 28.5* (108.2) million. Cash...

Amgen announces a recommended public cash offer to the shareholders of Nuevolution
Amgen announces a recommended public cash offer to the shareholders of Nuevolution

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong,...

Nuevolution AB (publ) Announces its Results for the First Quarter of 2019
Nuevolution AB (publ) Announces its Results for the First Quarter of 2019

Nuevolution AB (publ) announces its report for the first quarter of 2019. The report is available on the company's home page (www.nuevolution.com). The following is taken from the quarterly report.

Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has selected a second target under the collaboration and license...

Rhode Island Headlines 

Massachusetts Headlines 

Entertainment